Ironwood Pharmaceuticals, Inc. - Class A (IRWD) — Analysis Summary
Ironwood Pharmaceuticals, Inc. - Class A (IRWD) has a market cap of $689.05M with year-over-year revenue growth of -15.7%. Net margin stands at 8.1%. The stock trades at a P/E ratio of 5.3.
Key Takeaways
- Revenue changed -15.7% year-over-year
- Net margin of 8.1%
- P/E ratio of 5.3
Compared to other companies in the PHARMACEUTICAL PREPARATIONS sector, IRWD posted revenue growth of -15.7% and trades at a P/E of 5.3.
Ironwood Pharmaceuticals, Inc. - Class A (IRWD)
UPDATED — ET · MARKET DATA POLYGON · FINANCIALS SEC EDGAR
Red Flags & WarningsHigh Risk Signals
Multiple material red flags are active and deserve closer underwriting before relying on any valuation output.
Shareholder equity is negative, which can signal balance-sheet stress.
Operating margin (60.1%) exceeds gross margin (0.0%) — check for other operating income or data classification issues
Operating margin at 60.1% — exceptionally high, typical only for monopolistic or IP-heavy businesses
Ironwood Pharmaceuticals Inc is a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal, or GI, and rare diseases. It is focused on the development and commercialization of inventive product opportunities in areas of unmet need, leveraging its demonstrated expertise and capabilities in GI and rare diseases. LINZESS is its commercial product. LINZESS is also available for the treatment of adults with IBS-C or CIC in Mexico, adults with IBS-C or chronic constipation in Japan, and adults with IBS-C in China. Linaclotide is available under the trademarked name CONSTELLA for the treatment of adults with IBS-C or CIC and pediatric patients ages 6-17 years old with FC in Canada, and to adults with IBS-C in certain European countries.
Sector
PHARMACEUTICAL PREPARATIONS
Employees
100
Headquarters
BOSTON, MA
Exchange
XNAS
Systematic competitive advantage assessment based on 4yr data
This assessment is based on quantitative analysis of historical financial data and does not constitute investment advice. Moat ratings may change with industry and competitive dynamics.
First version surfaces recent SEC Forms 3, 4, and 5 activity. It does not yet parse individual buy/sell transactions.
Capital Structure
Cash Flow
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.